New data analyses presented at this year’s 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), show Januvia® (sitagliptin) as monotherapy, or in combination with metformin, provides significant blood sugar lowering over two years and is generally well tolerated.
“It is important that we continue to understand how DPP-4 inhibitors can be used in a variety of treatment settings. Monotherapy data for DPP-4 inhibitors are particularly useful for those patients who are unable to tolerate metformin.
"It is also encouraging to see data confirming that glycaemic control can be maintained for up to two years in a high proportion of patients treated with sitagliptin alone, or as an add-on to metformin, commented Professor John Wilding, Head of Diabetes and Endocrinology Clinical Research Unit at the University Hospital Aintree, Liverpool.
“These data add to existing evidence demonstrating the sustained effect of sitagliptin to maintain glycaemic control over two-years, complementing the expansion of this DPP-4 inhibitor’s indicated uses.”
Sitagliptin is a highly selective, once-daily DPP-4 inhibitor that enhances a natural body system called the incretin system, to help regulate blood sugar by increasing levels of active GLP-1 and GIP hormones; it inhibits DPP-4 over 24 hours.
Sitagliptin was the first approved medicine in the DPP-4 inhibitor class of oral treatments. It has been approved in over 80 countries, and to date there have been more than 15 million prescriptions dispensed worldwide and over a quarter of a million prescriptions dispensed in the UK since its launch in April 2007.